Baxter topped Q1 expectations and delivered a four percent sales increase that allowed the company to raise its 2017 forecast.
Stryker CEO Kevin Lobo reported continued momentum in robotics and 3D printing technology, and told investors he was not concerned about increased competition in either field.
A team of Australian scientists has just completed a phase one human clinical trial with an ingestible biosensor that can measure gas produced by the gut, and potentially transmit results to a connected smartphone.
GE continues to report “solid” performance for its healthcare sector, despite what CEO Jeffrey Immelt called “slow growth in a volatile environment” and challenges in other segments
Scientists in South Korea are mining the biomedical potential of both gold and graphene to design a more flexible brain-machine interface (BMI) that can transmit clearer signals while causing minimal damage to brain tissue, said researchers.
Siemens is looking to expand its portfolio of population health management (PHM) solutions with the acquisition of San Francisco-based tech firm Medicalis, which specializes in tools that maximize efficiency in clinical decisions, imaging workflow, and scheduling management.
Medtronic has confirmed a $6.1 billion cash deal with Cardinal Health and the divestment of its patient care, deep vein thrombosis, and nutritional insufficiency businesses, as well as 17 manufacturing facilities. Senior leadership at Medtronic stated they expect the businesses to “thrive” at Cardinal Health.
With Verily’s new “investigative watch,” the only information the clinical trial participant can view is the time and date, but researchers have access to a host of physiological data and biomarkers, including heart rate, activity data, and electrocardiograms (ECGs).
The FDA has compiled a list of over 70 class I medical devices that will no longer be subject to premarket notification requirements, effective immediately.
The National Health Service (NHS) in England will soon be commissioning mechanical thrombectomy services at 24 neuro centers around the country, which is expected to expand access to over 8,000 NHS patients in the coming years.